Topical Antifungal Paste Segmentation for Recurrence Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for fungal infections, particularly those caused by Candida overgrowth, often rely on steroid-based creams that provide temporary relief but can lead to fungal resurgence and immune system suppression, necessitating a non-steroidal solution that effectively reduces symptoms and prevents recurrence.
Innovation Solution
Topical anti-fungal pastes composed of a combination of antifungal agents, such as imidazoles and polyenes, along with an excipient inert powder and a pharmaceutically acceptable carrier, which minimize fungal resistance and maintain immune function, suitable for infants, children, and immunocompromised individuals.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If steroid-based antifungal creams are used, then symptom relief is rapid, but fungal resurgence occurs and immune system is suppressed
Solution Approach 1:
The treatment is divided into two distinct phases: an initial intensive phase using combination antifungal creams to rapidly control symptoms and fungal growth, followed by a maintenance phase using antifungal powder to prevent recurrence. This segmentation allows rapid symptom relief while avoiding long-term steroid use that causes resurgence.
Solution Approach 2:
The treatment protocol employs periodic action by alternating between intensive combination cream applications during acute phases and maintenance powder applications during remission phases. This periodic approach provides rapid relief when needed while minimizing immune suppression through reduced steroid exposure over time.
2Speed
If steroid-based antifungal creams are used, then symptom relief is rapid, but immune system suppression occurs
Solution Approach 1:
The treatment separates steroid use to only the initial intensive phase, excluding steroids from the long-term maintenance phase. This segmentation provides rapid symptom relief when steroids are most beneficial while eliminating prolonged immune system suppression.
Solution Approach 2:
Steroid-based combination creams are applied preliminarily during the intensive phase to rapidly control severe symptoms and inflammation, after which the treatment transitions to steroid-free maintenance therapy, thus achieving rapid relief without sustained immune suppression.
3Reliability
If combination antifungal therapy is used, then fungal resistance is minimized, but treatment complexity increases
Solution Approach 1:
The complex combination therapy is segmented into two distinct stages: an intensive phase using combination creams for rapid fungal control, and a maintenance phase using simpler antifungal powder applications. This segmentation maintains resistance prevention benefits while reducing overall treatment complexity over time.
Solution Approach 2:
The treatment extracts and removes steroids from the long-term maintenance phase, retaining only essential antifungal components in the powder formulation. This extraction maintains fungal resistance prevention through continued antifungal activity while simplifying the treatment regimen by eliminating steroid-related complexity.
Data Source
AI summary
Described herein are topical anti-fungal pastes and methods that treat fungal infections of the skin, reduce the severity and duration of symptoms of fungal infections of the skin, and prevent recurrence of fungal infections. The topical pastes described herein are composed of an admixture of one or more antifungal agents, excipient inert powder, and a pharmaceutically acceptable topical carrier. The compositions and methods described herein minimize fungal resistance and maximize the number of targeted fungal strains. Additionally, the compounds and methods do not suppress the body's immune system either locally or systemically, thus allowing for a faster restoration of normal skin flora. The compositions and methods described herein are particularly suitable for use in infants and children as well as in immunocompromised individuals, diabetics, and the obese.